Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

M Veronica Dioverti; David C Gaston; C Paul Morris; Carol Ann Huff; Tania Jain; Richard Jones; Viki Anders; Howard Lederman; Jacqueline Saunders; Heba H Mostafa; Robin K Avery

doi:10.1093/ofid/ofac064

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients

Open Forum Infect Dis. 2022 May 26;9(6):ofac064. doi: 10.1093/ofid/ofac064. eCollection 2022 Jun.

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
² Division of Medical Microbiology, Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
³ Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
⁴ Oncology Investigational Drug Service Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Abstract

Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.

Keywords: B-cell-depleted; monoclonal antibodies; prolonged SARS-CoV-2.